A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD
Researchers are comparing TNX-102 SL and placebo to find out how the approaches affect post-traumatic stress symptoms in people with PTSD.
Understand this study
What is this study about?
Researchers are comparing TNX-102 SL and placebo to find out how the approaches affect post-traumatic stress symptoms in people with PTSD.
Who could participate?
This study is for people with PTSD. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.
- Listed locations
- Phoenix and 29 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 192
- Sponsor
- Tonix Pharmaceuticals, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT03841773
- Official title
Show the full official title
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD Taken Daily at Bedtime (Protocol No. TNX-CY-P302)
Recruitment & locations
Phoenix · Little Rock · Rogers
27 more locations
- Beverly Hills
- Oceanside
- Orange
- Panorama City
- Riverside
- San Diego
- Temecula
- Colorado Springs
- Norwich
- Washington D.C.
- Jacksonville
- North Miami
- Orlando
- Tampa
- Alpharetta
- Lincolnwood
- Boston
- New Bedford
- Flowood
- St Louis
- Las Vegas
- Oklahoma City
- Portland
- Salem
- Memphis
- Austin
- Dallas
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are comparing TNX-102 SL and placebo to find out how the approaches affect post-traumatic stress symptoms in people with PTSD.
Who is behind this study?
The study sponsor is Tonix Pharmaceuticals, Inc.
Does this study involve medication?
Yes. The study involves medication, including TNX-102 SL and Placebo SL Tablets.
Who can participate?
This study is for people with PTSD. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
